CA
NZ
UK
AU
IND
US
…
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Inhibikase Therapeutics is a clinical-stage biopharmaceutical company developing oral kinase inhibitors targeting central nervous system disorders, with a focus on Parkinson’s disease and related neurodegenerative indications. Long-term growth may be driven by clinical trial progress, potential regulatory approval in high unmet-need indications and licensing or partnership opportunities, and investors may find the company attractive for exposure to a specialized small-molecule platform addressing neurodegeneration.
The most important investment risks are clinical and regulatory failure, limited cash runway requiring equity or debt financing, and strong competition in neurodegenerative drug development.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -48.26M | -27.52M | -19.03M | -18.05M | -14.79M |
| Net income | -48.26M | -27.52M | -19.03M | -17.91M | -14.81M |
| Selling general administrative | 23.56M | 11.38M | 6.68M | 6.22M | 6.51M |
| Gross profit | -0.06M | -0.03M | -13.36M | 0.12M | 3.10M |
| Reconciled depreciation | 0.06M | 0.03M | 0.18M | 0.01M | - |
| Ebit | -53.35M | -27.52M | -19.03M | -18.13M | -14.77M |
| Ebitda | -53.29M | -27.49M | -18.85M | -18.12M | -14.77M |
| Depreciation and amortization | 0.06M | 0.03M | 0.18M | 0.01M | - |
| Operating income | -51.97M | -28.59M | -20.09M | -18.13M | -14.77M |
| Other operating expenses | 51.97M | 28.59M | 20.35M | 18.13M | 14.77M |
| Interest expense | - | - | 0.07M | 0.07M | 0.02M |
| Interest income | 3.72M | 1.07M | 0.89M | 0.07M | - |
| Net interest income | 3.72M | 1.07M | 0.89M | 0.07M | -0.02M |
| Income tax expense | - | - | -0.15M | -0.15M | 0.02M |
| Total revenue | 0.00M | 0.00M | 0.26M | 0.12M | 3.10M |
| Total operating expenses | 51.97M | 28.56M | 6.73M | 18.13M | 14.77M |
| Cost of revenue | 0.06M | 0.03M | 13.62M | - | - |
| Total other income expense net | 3.72M | 1.07M | 1.06M | 0.07M | -0.02M |
| Net income from continuing ops | -48.26M | -27.52M | -19.13M | -18.05M | -14.79M |
| Net income applicable to common shares | - | - | - | - | -14.79M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 181.20M | 98.60M | 14.51M | 24.94M | 42.47M |
| Other current assets | 1.35M | 0.91M | 0.96M | 0.16M | 1.50M |
| Total liab | 8.30M | 3.73M | 3.53M | 3.90M | 4.05M |
| Total stockholder equity | 172.90M | 94.87M | 10.98M | 21.04M | 38.42M |
| Other current liab | 7.14M | 2.68M | 2.26M | 2.40M | 2.72M |
| Common stock | 0.13M | 0.07M | 0.01M | 0.03M | 0.03M |
| Capital stock | 0.13M | 0.07M | 0.01M | 0.03M | 0.03M |
| Retained earnings | -142.68M | -94.42M | -66.90M | -47.87M | -29.82M |
| Other assets | - | - | 0.00M | - | 1.61M |
| Cash | 139.22M | 56.49M | 9.17M | 7.19M | 40.75M |
| Total current liabilities | 8.30M | 3.73M | 3.44M | 3.70M | 4.05M |
| Net debt | -139.22M | -56.38M | -8.54M | -6.84M | -40.50M |
| Short term debt | - | 0.11M | 0.53M | 0.15M | 0.25M |
| Short long term debt | - | - | - | - | 0.25M |
| Short long term debt total | - | 0.11M | 0.62M | 0.35M | 0.25M |
| Other stockholder equity | 315.43M | 189.25M | 77.87M | 68.78M | 68.21M |
| Total current assets | 180.11M | 98.45M | 14.21M | 24.37M | 42.47M |
| Net tangible assets | - | - | - | - | 38.42M |
| Short term investments | 39.54M | 41.05M | 4.09M | 15.86M | - |
| Net receivables | - | - | 0.00M | 0.04M | 0.11M |
| Inventory | - | - | - | 1.12M | 0.11M |
| Accounts payable | 1.16M | 0.94M | 0.65M | 1.15M | 1.09M |
| Accumulated other comprehensive income | 0.02M | -0.04M | 0.00M | 0.10M | - |
| Non currrent assets other | 1.10M | 0.00M | -0.00M | 15.85M | - |
| Non current assets total | 1.10M | 0.15M | 0.30M | 0.57M | 0.00M |
| Capital lease obligations | 0.00M | 0.11M | 0.24M | 0.35M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 2.51M | -37.00M | 18.74M | -16.01M | - |
| Change to liabilities | - | - | - | - | -2.96M |
| Total cashflows from investing activities | 2.05M | -37.00M | 11.66M | - | - |
| Net borrowings | - | - | 0.00M | - | -0.04M |
| Total cash from financing activities | 108.46M | 103.48M | 8.41M | -0.20M | 41.09M |
| Change to operating activities | - | - | - | - | 1.30M |
| Net income | -48.26M | -27.52M | -19.03M | -18.05M | -14.79M |
| Change in cash | 82.73M | 47.33M | 1.98M | -33.56M | 26.80M |
| Begin period cash flow | 56.49M | 9.17M | 7.19M | 40.75M | 13.95M |
| End period cash flow | 139.22M | 56.49M | 9.17M | 7.19M | 40.75M |
| Total cash from operating activities | -27.79M | -19.15M | -18.09M | -17.35M | -14.30M |
| Issuance of capital stock | 107.62M | 103.48M | 8.54M | 0.00M | 41.14M |
| Depreciation | 0.06M | 0.03M | 0.18M | 0.01M | - |
| Other cashflows from investing activities | - | - | -0.24M | - | - |
| Change to inventory | - | - | - | - | 1.30M |
| Change to account receivables | - | 0.00M | 0.04M | 0.07M | -0.11M |
| Other cashflows from financing activities | - | 103.48M | -0.14M | -16.01M | 0.00M |
| Change to netincome | - | - | - | - | 2.25M |
| Capital expenditures | 0.01M | 0.00M | 0.01M | 0.24M | 0.00M |
| Change in working capital | 0.06M | 0.20M | 0.23M | 0.17M | -1.76M |
| Stock based compensation | 15.31M | 8.14M | 0.50M | 0.46M | 1.53M |
| Other non cash items | 5.05M | 0.20M | 0.03M | 0.07M | 0.72M |
| Free cash flow | -27.79M | -19.15M | -18.10M | -17.59M | -14.30M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| IKT Inhibikase Therapeutics Inc |
-0.12 7.19% |
1.55 | - | - | 10.39 | 2.17 | 0.59 | 0.34 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
1000 N. West Street, Wilmington, DE, United States, 19801
302 295 3800
35
| Name | Title | Year Born |
|---|---|---|
| Dr. Milton H. Werner Ph.D. | CEO, Pres & Director | 1963 |
| Mr. Joseph Frattaroli CPA | Chief Financial Officer | 1962 |
| Dr. Roger Rush | Head of Preclinical Research | NA |
| Dr. Surendra Singh | Head of Chemistry, Manufacturing & Controls | NA |
| Dr. Charles Warren Olanow B.Sc., F.R.C.P.C., M.D. | Medical Consultant, CEO of Clintrex Research Corp. & Science Advisor | NA |
| Dan Williams | Controller | NA |
| Dr. Milton H. Werner Ph.D. | CEO, President & Director | 1964 |
| Mr. Garth Lees-Rolfe | Chief Financial Officer | NA |
| Dr. Charles Warren Olanow B.Sc., F.R.C.P.C., M.D. | CEO of Clintrex Research Corporation & Member of Scientific Advisory Board | NA |
| Mr. Mark T. Iwicki | CEO & Director | 1966 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...